



HIV BLOT 2.2

Instructions for Use

FOR RESEARCH USE ONLY
NOT FOR USE IN DIAGNOSTIC PROCEDURES

REVISION DATE 09/10
MAE0012-ENG-0

Note Changes Highlighted



(18 tests kit): 11032-018
(36 tests kit): 11032-036

NAME AND INTENDED USE

The **MP Diagnostics (MPD) HIV BLOT 2.2** is a qualitative enzyme immunoassay for the *in-vitro* detection of antibodies to human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) in human serum or plasma. This test kit is supplied for Research Use Only. It is not intended for use in the diagnosis or prognosis of disease.

INTRODUCTION

The **MP Diagnostics HIV BLOT 2.2** kit is intended as a supplemental antibody assay for research purposes only. The separated specific HIV-1 viral antigens incorporated onto the strips via electrophoretic and electrotransblot procedures, combined with a specific HIV-2 synthetic peptide on the same strip allow for further delineation of the antibody responses to specific viral proteins. Each strip also includes an internal sample addition control to minimize the risk of false negatives due to operational errors and to ensure the addition of samples.

DESCRIPTION OF SYMBOLS USED

The following are graphical symbols used in or found on **MP Diagnostics** products and packaging. These symbols are the most common ones appearing on medical devices and their packaging. Some of the common symbols are explained in more detail in European Standard BS EN 980:2008 and International Standard ISO 15223-1:2007.



Use by



Catalogue
Number



Batch Code
Synonyms for this are:
Lot Number
Batch Number



Caution



Temperature Limitation



Consult
Instructions for
Use



Manufacturer



Do not reuse



Contains sufficient
for <n> tests
















Harmful (Xn)/
Irritant (Xi)

CHEMICAL & BIOLOGICAL PRINCIPLES OF THE PROCEDURE

The nitrocellulose strips are incorporated with separated, bound antigenic proteins from partially purified inactivated HIV-1 using electrophoretic blotting, plus a specific HIV-2 synthetic peptide on the same strip. Individual nitrocellulose strips are incubated with diluted serum or plasma and controls. Specific antibodies to HIV-1 and HIV-2 if present in the specimens will bind to the HIV-1 proteins and HIV-2 peptide on the strips. The strips are washed to remove unbound materials. Antibodies that bind specifically to HIV proteins can be visualized using a series of reactions with goat anti-human IgG conjugated with alkaline phosphatase and the substrate BCIP/NBT.

KIT COMPONENTS

	<u>Component Description</u>	<u>Quantity Provided</u>
ANTIGEN STRIPS	NITROCELLULOSE STRIPS Incorporated with HIV-1 viral lysate, a specific HIV-2 envelope peptide and a serum addition control band. Keep dry and away from light.	Available in 18 or 36 strips
CONTROL   	NON-REACTIVE CONTROL Inactivated normal human serum non-reactive for Hepatitis B surface antigen (HBsAg), antibodies to HIV-1/2, and anti-HCV. Contains sodium azide and thimerosal as preservatives.	1 vial (80 µl)
CONTROL   	STRONG REACTIVE CONTROL Inactivated human serum with high titered antibodies to HIV-1 and HIV-2 and non-reactive for HBsAg & anti-HCV. Contains sodium azide and thimerosal as preservatives.	1 vial (80 µl)
CONTROL WEAK  	WEAK REACTIVE CONTROL Inactivated human serum with low titered antibodies to HIV-1 ONLY and non-reactive for HBsAg, anti-HIV-2 and anti-HCV. Contains sodium azide and thimerosal as preservatives.	1 vial (80 µl)
BUF STOCK 10x 	STOCK BUFFER CONCENTRATE (10x) Tris buffer with heat inactivated normal goat serum. Contains thimerosal as preservative.	1 bottle (20 ml)
BUF WASH 20x 	WASH BUFFER CONCENTRATE (20x) Tris with Tween-20. Contains thimerosal as preservative	1 bottle (70 ml)
CONJUGATE 	CONJUGATE Goat anti-human IgG conjugated with alkaline phosphatase. Contains sodium azide as preservative	1 vial (160 µl)
SUBS BCIP / NBT  	SUBSTRATE Solution of 5-bromo-4-chloro-3-indolyl- phosphate (BCIP) and nitroblue tetrazolium (NBT).	1 bottle (100 ml)
POWDER BLOTTING	BLOTTING POWDER Non-fat dry milk	10 packets (1g each)
	Incubation Tray, 9 wells each	2 or 4 trays
	Instructions for Use	1 copy
	Forceps	1 pair

Note : Volume of reagents provided are sufficient for 4 runs.

WARNINGS AND PRECAUTIONS

1. For *Research* use only. Not for use in diagnostic procedures.
2. For Professional use only.

HEALTH AND SAFETY INFORMATION



CAUTION: This kit contains materials of human origin. No test method can offer complete assurance that human blood products will not transmit infection. **HANDLE ASSAY SPECIMENS, STRONG REACTIVE, WEAK REACTIVE AND NON-REACTIVE CONTROLS AS POTENTIALLY INFECTIOUS AGENTS.** It is recommended that the components and test specimens be handled using good laboratory working practices. They should be disposed of in accordance with established safety procedures.

The **Strong Reactive Control**, **Weak Reactive Control** and **Non-Reactive Control** contain Thimerosal and Sodium azide while Stock Buffer Concentrate and Wash Buffer Concentrate contain Thimerosal and Conjugate contains Sodium azide. Sodium Azide can react with copper and lead used in some plumbing systems to form explosive salts. The quantities used in this kit are small, nevertheless when disposing of azide-containing materials they should be flushed away with relatively large quantities of water to prevent metal azide buildup in plumbing system. The following are the appropriate Risk (R) phrases.

R22 Harmful if swallowed.

The **Substrate** contains 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium which is classified per applicable European Economic Community (EEC) Directives as harmful (Xn). The following are the appropriate Risk (R) phrases.

R20/21/22 Harmful by inhalation, in contact with skin and if swallowed.

1. Avoid Microbial contamination of reagents when opening and removing aliquots from the original vials or bottles.
2. Do not pipette by mouth.
3. Handle test specimens, nitrocellulose strips, Reactive, Weak Reactive and Non-Reactive Controls as potentially infectious agents.
4. Wear laboratory coats and disposable gloves while performing the assay. Discard gloves in bio-hazard waste-bags. Wash hands thoroughly afterwards.
5. It is highly recommended that this assay be performed in a biohazard cabinet.
6. Keep materials away from food and drink.
7. In case of accident or contact with eyes, rinse immediately with plenty of water and seek medical advice.
8. Consult a physician immediately in the event that contaminated materials are ingested or come in contact with open lacerations, or other breaks in the skin.
9. Wipe spills of potentially infectious materials immediately with absorbent paper and swab the contaminated area with 1% sodium hypochlorite solution before work is resumed. Sodium hypochlorite should not be used on acid containing spills unless the area is wiped dry with absorbent paper first. Material used (including disposable gloves) should be disposed off as potentially biohazard material. Do not autoclave material containing sodium hypochlorite.
10. Autoclave all used and contaminated materials at 121°C at 15 p.s.i. for 30 minutes before disposal. Alternatively, decontaminate materials in 5% sodium hypochlorite solution for 30-60 minutes before disposal in biohazard waste-bags.
11. Decontaminate all used chemicals and reagents by adding sufficient volume of sodium hypochlorite to make a final concentration of at least 1%. Leave for 30 minutes to ensure effective decontamination.
12. We do not recommend re-use of incubation trays.

ANALYTICAL PRECAUTIONS

1. Optimal assay performance requires **STRICT ADHERENCE** to the assay procedure described in the Instructions for Use. Deviations from the procedure may lead to aberrant results.
2. **DO NOT MODIFY OR SUBSTITUTE REAGENTS FROM ONE KIT LOT TO ANOTHER.** Controls, conjugate and Western Blot strips are matched for optimal performance. Use only the reagents supplied with the kit.
3. Do not use kit components beyond the expiry date printed on the kit box.
4. Avoid microbial contamination of the reagents when opening and removing aliquots from the original vials or bottles, as this will prematurely reduce the shelf life of the kits and give erroneous results. Use aseptic techniques including pipettes or disposable pipette tips when drawing aliquots from vials.
5. The kit controls should be assayed concurrently with test specimens for each test run.
6. Use a new pipette tip for each specimen aliquot to prevent cross contamination.
7. For best results dispense all reagents while cold and return to 2°C to 8°C storage as soon as possible.
8. It is recommended that glassware to be used with the reagents should be washed with 2M hydrochloric acid and rinsed thoroughly with distilled or deionised water prior to use.
9. Use only reagent grade quality, deionised or distilled water to dilute reagents.

10. All reagents must be mixed well before use.
11. Working Conjugate solution, Diluted Wash Buffer and Blotting Buffer should be **prepared fresh prior to use**.
12. The Working Conjugate solution should be prepared using a polypropylene container or beaker.
13. Do not expose reagents or perform test in an area containing a high level of chemical disinfectant fumes (e.g. hypochlorite fumes) during storage or during incubation steps. Contact inhibits colour reaction. Also do not expose reagents to strong light.
14. The assay should preferably be performed at room temperature ($25^{\circ}\text{C} \pm 3^{\circ}\text{C}$).
15. Make sure that the test strips are laid with the numbers on the strips facing upwards.
16. For Western Blot Assay, it is important to use a rocking platform shaker and not a rotary shaker. Otherwise, performance of the kit will be compromised. The recommended speed and tilt angle of the shaker are 12 to 16 cycles per minute, and 5 to 10 degrees, respectively.
17. Ensure that automated equipment if used is validated before use.
18. Ensure that the specimens are added away from the strip. Tray can be tilted and specimen added where the buffer is collected at lower end. This prevents dark spot formation due to specimen addition on the strip.
19. Avoid the use of self-defrosting freezers for the storage of reagents and samples.
20. We do not recommend the use of diluted or lyophilized samples, as they may give false results.

STORAGE

1. Store MPD HIV BLOT 2.2 kit and its components at 2°C to 8°C when not in use.
2. All test reagents and strips when stored at 2°C to 8°C , are stable until the expiry date given on the kit. Do not freeze reagents.
- A. **Antigen strips**
 - Avoid unnecessary exposure of antigen strips to light.
- B. **Reagents**
 - Store reagents in their original vials or bottles, and they should be capped for storage.
 - Dispense all reagents while cold and return to 2°C to 8°C storage as soon as possible.
 - Precipitates may form when the Substrate is stored at 2°C to 8°C . This will not affect the performance of the kit.

Caution: Avoid unnecessary exposure of substrate to light.

SPECIMEN COLLECTION, TRANSPORT AND STORAGE

Serum or plasma samples collected in EDTA, heparin or sodium citrate may be used. Before storage, ensure that blood clot or blood cells have been separated by centrifugation.

Samples should be stored at 2°C to 8°C if the test is to be run within 7 days of collection or frozen at -20°C or colder if the test is to be delayed for more than 7 days. Clear, non-hemolyzed samples are preferred. Lipemic, icteric or contaminated (particulate) samples should be filtered ($0.45\mu\text{m}$) or centrifuged before testing.

Samples can be inactivated but this is not a requirement for optimal test performance. Inactivate as follows:

1. Loosen cap of sample container.
2. Heat-inactivate sample at 56°C for 30 minutes in a water bath.
3. Allow sample to cool down before retightening cap.
4. Sample can be stored frozen until analysis.

Repeated freeze-thawing of sample is not recommended.

ADDITIONAL MATERIALS REQUIRED BUT NOT PROVIDED

- Deionized or distilled water
- Disposable gloves
- Rocking platform (designed with a rocking speed range of 12 to 16 cycles per minute, and which moves through a 5° to 10° tilt to wash membranes evenly)
- Pipettors and tips of appropriate volume
- Aspirator with sodium hypochlorite trap
- 56°C water bath (optional)
- Sodium hypochlorite for decontamination

PREPARATION OF REAGENTS

1. **DILUTED WASH BUFFER**
 - (a) DILUTED WASH BUFFER should be **prepared fresh prior to use**.
 - (b) Dilute 1 volume of WASH BUFFER CONCENTRATE (20X) with 19 volumes of reagent grade water. Mix well.
2. **BLOTTING BUFFER**
 - (a) BLOTTING BUFFER should be **prepared fresh prior to use**.
 - (b) Dilute 1 volume of STOCK BUFFER CONCENTRATE (10X) with 9 volumes of reagent grade water. Mix well.
 - (c) Add 1 g of BLOTTING POWDER to every 20 ml of the diluted STOCK BUFFER prepared in step 2(b) above. Stir to ensure powder dissolves completely.
 - (d) Stir again before dispensing.
3. **WORKING CONJUGATE SOLUTION**

Note : Prepare solution in polypropylene container / beaker.

 - (a) WORKING CONJUGATE SOLUTION should be **prepared fresh prior to use**.
 - (b) For **RAPID ASSAY PROTOCOL**, prepare WORKING CONJUGATE SOLUTION by diluting CONJUGATE at 1:500 into BLOTTING BUFFER, for example, 10 µl CONJUGATE to 5ml BLOTTING BUFFER.
 - (c) For **OVERNIGHT ASSAY PROTOCOL**, prepare WORKING CONJUGATE SOLUTION by diluting CONJUGATE at 1:1000 into BLOTTING BUFFER, for example, 5 µl CONJUGATE to 5ml BLOTTING BUFFER.
4. **SUBSTRATE SOLUTION (ready to use)**
 - (a) Dispense directly the required volume from the bottle.
Use a clean pipette. Cap tightly after use.

AMOUNT OF REAGENTS REQUIRED FOR VARIOUS NUMBER OF STRIPS							
Reagents	NUMBER OF STRIPS TO BE USED						
	3	6	9	15	20	27	36
Diluted Wash Buffer (ml)	60	100	140	240	300	400	600
Blotting Buffer (ml)	20	40	60	80	100	120	160
Blotting Powder (g)	1	2	3	4	5	6	8
Working Conjugate Solution (ml)	7	13	19	31	41	55	73
Conjugate (µl), Rapid Assay	14	26	38	62	82	110	146
Conjugate (µl), Overnight Assay	7	13	19	31	41	55	73
Substrate Solution (ml)	7	13	19	31	41	55	73

ASSAY PROCEDURE - RAPID ASSAY

- Note:**
- a) Users can use either the rapid or overnight assay to run the tests. HIV bands are more developed and more bands may appear with the overnight assay, but the overall performance of the two assays is the same.
 - b) Aspirate all used chemicals and reagents into a trap containing Sodium hypochlorite.
 - c) All incubations are to be carried out on a rocking platform.

Caution: Some samples cause dark patches on the spot of the strip where they are added. To avoid this problem, one should ensure the following:-

- i. Sample should be added only after BLOTTING BUFFER is added.
- ii. Tilt the tray slightly by elevating either the top or bottom end of the tray. The Blotting Buffer will flow to the lower end of the tray. Add the sample where the Blotting Buffer is collected. When all the samples are added, return the tray back to its original flat position. Always ensure that the strips are kept wet during the process.

- iii. Alternatively, if tilting the tray is not desired, the samples may be added to the top or bottom end of the well. This way if dark patches showed, the reading of the strip results will not be affected

Procedure:

- | | | |
|-----|---|------------------------------------|
| 1. | Add 2 ml of DILUTED WASH BUFFER to each well. | 2 ml |
| 2. | Using forceps, carefully remove required number of STRIPS from the tube and place numbered side up into each well. Include strips for Strong Reactive, Weak Reactive and Non-Reactive controls. | |
| 3. | Incubate the strips for <u>1 to 2 minutes</u> at room temperature ($25 \pm 3^{\circ}\text{C}$) on a rocking platform (speed of 12 to 16 cycles per minute). Remove buffer by aspiration. (Note: Do not allow the strips to dry. Failure may result in watery marks on developed strips for some specimens.) | 2 minutes |
| 4. | Add 2 ml of BLOTTING BUFFER to each well. | 2 ml |
| 5. | Add 20 μl each of sera or controls to appropriate wells. Care should be taken to ensure specimens are not added directly on the strips. | 20 μl |
| 6. | Cover the tray with the cover provided and incubate for <u>1 hour</u> at room temperature ($25 \pm 3^{\circ}\text{C}$) on the rocking platform. | 60 minutes |
| 7. | Carefully uncover the tray to avoid splashing or mixing of samples. Tilt the tray to aspirate the mixture from the wells. Change aspirator tips between samples to avoid cross-contamination. | |
| 8. | Wash each strip 3 times with 2 ml of DILUTED WASH BUFFER allowing <u>5 minutes</u> soak on the rocking platform between each wash. | 3 x 2 ml |
| 9. | Add 2 ml of WORKING CONJUGATE SOLUTION to each well. | 2 ml |
| 10. | Cover tray and incubate for <u>1 hour</u> at room temperature ($25 \pm 3^{\circ}\text{C}$) on the rocking platform. | 60 minutes |
| 11. | Aspirate WORKING CONJUGATE SOLUTION from the wells. Wash as in step 8. | 3 x 2 ml |
| 12. | Add 2 ml of SUBSTRATE SOLUTION to each well. | 2 ml |
| 13. | Cover tray and incubate for <u>15 minutes</u> on the rocking platform. (Note: The reaction can be stopped before 15 minutes if all the bands are visible.) | 15 minutes |
| 14. | Aspirate the SUBSTRATE SOLUTION and rinse the strips at least three times with reagent grade water to stop the reaction (A dark background can result if washing is insufficient at this step). | 3 x 2 ml |
| 15. | Using forceps, gently remove strips onto paper towels. Cover with paper towels and dry. Alternatively, allow strips to dry in the wells of the tray. | |
| 16. | Mount strips on worksheet (non-absorbent white paper). Do not apply adhesive tape over the developed bands. Observe the bands (See Interpretation of Results) and grade the results. For storage, keep the strips in the dark. | |

ALTERNATIVE PROCEDURE - OVERNIGHT ASSAY
--

Procedure:

- | | | |
|----|---|-------------|
| 1. | Add 2 ml of DILUTED WASH BUFFER to each well. | 2 ml |
| 2. | Using forceps, carefully remove required number of STRIPS from the tube and place numbered side up into each well. Include strips for Strong Reactive, Weak Reactive and Non-Reactive controls. | |

3. Incubate the strips for 1 to 2 minutes at room temperature ($25 \pm 3^{\circ}\text{C}$) on a rocking platform (speed of 12 to 16 cycles per minute). Remove buffer by aspiration. (Note: Do not allow the strips to dry. Failure may result in watery marks on developed strips for some specimens.) **2 minutes**
4. Add 2 ml of BLOTTING BUFFER to each well. **2 ml**
5. Add 20 μl each of sera or controls to appropriate wells. **20 μl**
6. Cover the tray with the cover provided and incubate overnight (16 - 20 hours) at room temperature ($25 \pm 3^{\circ}\text{C}$) on the rocking platform. **overnight**
7. Carefully uncover the tray to avoid splashing or mixing of samples. Tilt the tray to aspirate the mixture from the wells. Change aspirator tips between samples to avoid cross-contamination.
8. Wash each strip 3 times with 2ml of DILUTED WASH BUFFER allowing 5 minutes soak on the rocking platform between each wash. **3 x 2 ml**
9. Add 2 ml of WORKING CONJUGATE SOLUTION to each well. **2 ml**
10. Cover tray and incubate for 30 minutes at room temperature ($25 \pm 3^{\circ}\text{C}$) on the rocking platform. **30 minutes**
11. Aspirate WORKING CONJUGATE SOLUTION from the wells. Wash as in step 8. **3 x 2 ml**
12. Add 2 ml of SUBSTRATE SOLUTION to each well. **2 ml**
13. Cover tray and incubate for 15 minutes on the rocking platform. (Note: The reaction can be stopped before 15 minutes if all the bands are visible.) **15 minutes**
14. Aspirate the SUBSTRATE SOLUTION and rinse the strips at least three times with reagent grade water to stop the reaction (A dark background can result if washing is insufficient at this step). **3 x 2 ml**
15. Using forceps, gently remove strips onto paper towels. Cover with paper towels and dry. Alternatively, allow strips to dry in the wells of the tray.
16. Mount strips on worksheet (non-absorbent white paper). Do not apply adhesive tape over the developed bands. Observe the bands (See Interpretation of Results) and grade the results. For storage, keep the strips in the dark.

SUMMARY OF ASSAY PROTOCOLS			
Reagents	Qty	Room Temp Rapid Assay	Room Temp Overnight Assay
Nitrocellulose strip	1	-	-
Wash Buffer	2 ml	1 - 2 mins	1 - 2 mins
Blotting Buffer	2 ml	-	-
Specimen	20 μl	60 mins	Overnight (16 - 20 hours)
Wash Buffer	3 x 2 ml	3 x 5 mins	3 x 5 mins
Conjugate	2 ml	60 mins	30 mins
Wash Buffer	3 x 2 ml	3 x 5 mins	3 x 5 mins
Substrate (Ready to use)	2 ml	15 mins (or less)	15 mins (or less)
Distilled Water	3 x 2 ml	-	-

QUALITY CONTROL

We recommend that the Non-Reactive, Strong Reactive and Weak Reactive controls be run with every assay regardless of the number of samples tested. In order for the results obtained from any assay to be considered valid, the following conditions must be met:

1. **NON-REACTIVE CONTROL**

No HIV-1 and HIV-2 specific bands should be observed on the Non-Reactive control strips. The band for the serum control should be visible (Fig 1c).

2. **STRONG REACTIVE CONTROL**

All relevant molecular weight bands must be evident. Figure 1a provides a guide to the relative positioning of bands visualized with the MPD HIV BLOT 2.2 and permits identification of bands observed for the STRONG REACTIVE CONTROL. The bands are p17, p24, p31, gp41, p51, p55, p66, gp120/gp160. Other bands associated with core antigens (p39, p42) may also be visible. Be careful not to misinterpret these as gp41. The envelope antigens, gp41, gp120/gp160 appear as diffuse bands as they are typical of glycoproteins; p55 viral band may appear faintly on the actual Strong Reactive Control strip due to low titer of anti-p55 in the Strong Reactive Control provided. The serum control band will be visible. The HIV-2 specific band should also be visible as shown in Figure 1a.

3. **WEAK REACTIVE CONTROL**

The Weak Reactive control provides a measure of the sensitivity of the kit. Weak bands at p24 and/or gp41 and gp120/gp160 should appear. Some additional weak bands may or may not be present. The serum control band will be visible (Fig 1b).

LIMITATIONS OF THE PROCEDURE

Optimal assay performance requires the strict adherence to the assay procedure described. Deviation from the recommended procedure may lead to aberrant results.

LIMITED EXPRESSED WARRANTY DISCLAIMER

The manufacturer makes no express warranty other than that the test kit will function as a Research Use Only assay within the specifications and limitations described in the product Instructions Manual when used in accordance with the instruction contained therein. The manufacturer disclaims any warranty express or implied, including such express or implied warranty with respect to merchantability, fitness for use or implied utility for any other purpose. The manufacturer is limited to either replacement of the product or refund of the purchase price of the product. The manufacturer shall not be liable to the purchaser or third parties for any damage, injury or economic loss howsoever caused by the product in the use or in the application thereof. The manufacturer makes no representation express or implied, that this product will not infringe the intellectual property rights of the third parties.

TECHNICAL PROBLEMS / COMPLAINTS TECHNICAL PROBLEMS / COMPLAINTS

Should there be a technical problem / complaint, please do the following:

1. Note the kit lot number, the expiry date and the strip lot number.
2. Retain the kits and the results that were obtained.
3. Contact the nearest MP Biomedicals office or your local distributor.

REFERENCES

1. V.C.W.Tsang, K. Hancock, M. Wilson, D.F. Palmer, S. Whaley, J.S. Mc Dougal, and S. Kennedy. March 1985. Developmental Procedure : Enzyme-linked Immuno-electro-transfer Blot technique for HTLV-III/LAV antibodies; CDC, Atlanta.
2. H. Towbin, T. Staehlin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76: 4350-4354.
3. J. Schupbach, M. Popovic, R. V. Gilden, M.A. Gonda, M. G. Sarngadharan and R. C. Gallo. 1984. Serological Analysis of subgroup of Human T-Lymphotropic retroviruses (HTLV-III) associated with AIDS. Science 224, 503-505.
4. M. G. Sarngadharan, M. Popovic, L. Bruch, J. Schupbach and R. C. Gallo. 1984. Antibodies reactive with human T-Lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 224, 506-608.

5. CDC. 1985. " Provisional public health service inter-agency recommendations for screening donated blood and plasma for antibody to the virus causing Acquired Immune Deficiency Syndrome" - United States Morbidity and Mortality Weekly Report 34 (1) :1-5.
6. Proposed WHO criteria for interpreting results from Western blot assays for HIV-1, HIV-2, and HTLV-I/HTLV-II, 1990, WHO Weekly Epidemiological Record No 37, p282-283.
7. F. Clavel, D. Guetard., F. Brun-Vezinet, et al. 1986 Isolation of a new human retrovirus from West African patients with AIDS. Science; 233:343-346.
8. F. Clavel., 1987. HIV-2, the West African AIDS virus. AIDS 1:135-140.
9. R.S. Tedder, A. Hughes, T. Corrah et al 1988. Envelope cross-reactivity in Western Blot for HIV-1 and HIV-2 may not indicate dual infection. Lancet 11:927-930.
10. Bottiger B., A. Karlsson, F. Andreasson et al. 1990. Envelope cross-reactivity between Human Immunodeficiency Virus Type 1 and Type 2 detected by different serological methods: Correlation between cross-neutralization and reactivity against the main neutralizing site. J. Virol. 64(7):3492-3499.
11. Centers for Disease Control. 2001. Revised Guidelines for HIV Counseling, Testing, and Referral and Revised Recommendations for HIV Screening of Pregnant Women --- United States, Morbid. Mortal. Weekly Rep. 50: RR-19.
12. Fiebig, E. W., D. J. Wright, B. D. Rawal, P. E. Garrett, R. T. Schumacher, L. Peddada, C. Heldebrant, R. Smith, A. Conrad, S. H. Kleinman, and M. P. Busch. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 17:1871-1879.
13. Ly, T. D., C. Edlinger, and A. Vabret. 2000. Contribution of combined detection assays of p24 antigen and anti-human immunodeficiency virus (HIV) antibodies in diagnosis of primary HIV infection by routine testing. J Clin Microbiol. 38:2459-2461.
14. Sethoe, S. Y., A. E. Ling, E. H. Sng, E. H. Monteiro, R. K. Chan. 1995. PCR as a confirmatory test for human immunodeficiency virus type 1 infection in individuals with indeterminate western blot (immunoblot) profiles. J Clin Microbiol. 33:3034-3036.
15. Constantine, N. T. and H. Zink. 2005. HIV testing technologies after two decades of evolution. Indian J Med Res. 121:519-538.
16. World Health Organization. 2004. Guidelines for HIV Diagnosis and monitoring of antiretroviral therapy. Regional Office for South-East Asia, New Delhi, India.


Manufacturer:



MP Biomedicals Asia Pacific Pte Ltd
 2 Pioneer Place
 Singapore 627885

Tel. No. : +65 775 0008
 Fax No. : +65 774 6146
 Email: enquiry_ap@mpbio.com

FIGURE 1



- a. Strong Reactive Control (Reactive for HIV-1 and HIV-2)
- b. Weak Reactive Control (Reactive for HIV-1 only).
- c. Non-Reactive Control.
- d. A typical HIV-2 seropositive serum.